|
|
Article: Millennium's Velcade Entering Phase III For Multiple Myeloma.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Millennium Pharmaceuticals Inc. initiated a Phase III trial of newly named Velcade, its drug candidate most recently known as MLN341, in patients with multiple myeloma.
The company said it filed for trademark registration for the name Velcade (bortezomib) for injection, which also has been known previously as LDP-341 and PS-341.
Cambridge, Mass.-based Millennium said the Phase III trial will be a randomized, open-label, multicenter trial to compare Velcade with high-dose dexamethasone. The trial is planned for 60 sites in the U.S., Canada and Europe with about 600 patients participating, all of whom have experienced disease ...